Exposure to acellular blood products and risk of HIV infection in hemophiliacs from Belo Horizonte, Brazil.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Exposure to acellular blood products and risk of HIV infection in hemophiliacs from Belo Horizonte, Brazil.

Rev Inst Med Trop Sao Paulo. 1992 May-Jun;34(3):227-32. Unique Identifier : AIDSLINE MED/94098135
Proietti FA; Proietti AB; Costa MF; Antunes CM; Guimaraes MD; Paulino UH; Souza CJ; Melo L; Munoz A; Dep. Propedeutica Complementar, Universidade Federal de Minas; Gerais, Brazil.

Abstract: Results of a HIV prevalence study conducted in hemophiliacs from Belo Horizonte, Brazil are presented. History of exposure to acellular blood components was determined for the five year period prior to entry in the study, which occurred during 1986 and 1987. Patients with coagulations disorders (hemophilia A = 132, hemophilia B = 16 and coagulation disorders other than hemophilia = 16) were transfused with liquid cryoprecipitate, locally produced, lyophilized cryoprecipitate, imported from Sao Paulo (Brazil) and factor VIII and IX, imported from Rio de Janeiro (Brazil), Europe, and United States. Thirty six (22%) tested HIV seropositive. The univariate and multivariate analysis (logistic model) demonstrated that the risk of HIV infection during the study period was associated with the total units of acellular blood components transfused. In addition, the proportional contribution of the individual components to the total acellular units transfused, namely a increase in factor VIII/IX and lyophilized cryoprecipitate proportions, were found to be associated with HIV seropositivity. This analysis suggest that not only the total amount of units was an important determinant of HIV infection, but that the risk was also associated with the specific component of blood transfused.

Keywords: Adolescence Adult Blood Coagulation Disorders/COMPLICATIONS/EPIDEMIOLOGY/IMMUNOLOGY/ THERAPY Blood Transfusion/*ADVERSE EFFECTS Brazil/EPIDEMIOLOGY Comparative Study Factor IX/*ADVERSE EFFECTS Factor VIII/*ADVERSE EFFECTS Hemophilia/COMPLICATIONS/*EPIDEMIOLOGY/IMMUNOLOGY/THERAPY Human HIV Antibodies/BLOOD HIV Infections/*EPIDEMIOLOGY/ETIOLOGY/IMMUNOLOGY HIV Seroprevalence *HIV-1 Logistic Models Male Risk Factors Support, Non-U.S. Gov't Urban Population/*STATISTICS & NUMER DATA JOURNAL ARTICLE
940430
M9440890

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .